_id
69130c5bccc777a4e85d7cf9
Ticker
KYKOY
Name
Kyowa Kirin Co., Ltd.
Exchange
OTCGREY
Address
1-9-2, Otemachi, Tokyo, Japan, 100-0004
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.kyowakirin.com
Description
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. It also develops OTL-203 for the treatment of mucopolysaccharidosis type IH (hurler syndrome); KHK4083/AMG 451 to treat atopic dermatitis, prurigo nodularis, and asthma; OTL-201 for the treatment of mucopolysaccharidosis type IIIA (sanfilippo syndrome type A); ziftomenib for treating R/R acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951 for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123 to treat x-linked hypophosphatemia; KK2845 for the treatment of acute myeloid leukemia; KK4277 for treating systemic and cutaneous lupus erythematosus; Lumicef to treat palmoplantar pustulosis; KK2260 and KK2269 for the treatment of solid tumors; and KK8398 for the treatment of achondroplasia. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Last Close
14.482
Volume
-
Current Price
14.482
Change
0
Last Updated
2026-01-04T16:17:17.382Z
Image
-
Ipo Date
-
Market Cap
7581174784
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.996
Sentiment Sources
4
Current Quarter
2024-06-30
Revenue
127404000000
Cost Of Revenue
33882000000
Gross Profit
93522000000
Operating Expenses
102871000000
Operating Income
24533000000
Interest Expense
729000000
Pretax Income
28421000000
Net Income
23144000000
Eps
43.85621755749144
Dividends Per Share
0
Shares Outstanding
523489469
Income Tax Expense
-
EBITDA
-
Operating Margin
19.256067313428147
Total Other Income Expense Net
-
Cash
311135000000
Short Term Investments
1463000000
Receivables
126274000000
Inventories
77370000000
Total Current Assets
543420000000
Property Plant Equipment
104301000000
Total Assets
1070009000000
Payables
114745000000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
207321000000
Equity
862688000000
Bs_currency_symbol
JPY
Depreciation
6466000000
Change In Working Capital
-13668000000
Cash From Operations
27645000000
Capital Expenditures
26427000000
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-21985000000
Cf_currency_symbol
JPY
PE
30.8128
PB
0.008858945586003282
ROE
2.682777551096109
ROA
2.1629724609793
FCF
1218000000
Fcf Percent
0.009560139399076953
Piotroski FScore
4
Health Score
46
Deep Value Investing Score
9
Defensive Investing Score
7.5
Dividend Investing Score
5
Economic Moat Investing Score
8.3
Garp Investing Score
8
Growth Investing Score
6.5
Momentum Investing Score
5.5
Net Net Investing Score
9.5
Quality Investing Score
8
Value Investing Score
8
Quarters > 0 > quarter
2024-06-30
Quarters > 0 > income Statement > revenue
127404000000
Quarters > 0 > income Statement > cost Of Revenue
33882000000
Quarters > 0 > income Statement > gross Profit
93522000000
Quarters > 0 > income Statement > operating Expenses
102871000000
Quarters > 0 > income Statement > operating Income
24533000000
Quarters > 0 > income Statement > interest Expense
729000000
Quarters > 0 > income Statement > pretax Income
28421000000
Quarters > 0 > income Statement > net Income
23144000000
Quarters > 0 > income Statement > eps
43.85621755749144
Quarters > 0 > income Statement > dividends Per Share
0
Quarters > 0 > income Statement > shares Outstanding
527724489
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
19.256067313428147
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
JPY
Quarters > 0 > balance Sheet > cash
311135000000
Quarters > 0 > balance Sheet > short Term Investments
1463000000
Quarters > 0 > balance Sheet > receivables
126274000000
Quarters > 0 > balance Sheet > inventories
77370000000
Quarters > 0 > balance Sheet > total Current Assets
543420000000
Quarters > 0 > balance Sheet > property Plant Equipment
104301000000
Quarters > 0 > balance Sheet > total Assets
1070009000000
Quarters > 0 > balance Sheet > payables
114745000000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
207321000000
Quarters > 0 > balance Sheet > equity
862688000000
Quarters > 0 > balance Sheet > currency_symbol
JPY
Quarters > 0 > cash Flow > net Income
23145000000
Quarters > 0 > cash Flow > depreciation
6466000000
Quarters > 0 > cash Flow > change In Working Capital
-13668000000
Quarters > 0 > cash Flow > cash From Operations
27645000000
Quarters > 0 > cash Flow > capital Expenditures
26427000000
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-21985000000
Quarters > 0 > cash Flow > currency_symbol
JPY
Quarters > 0 > ratios > PE
43.85621755749144
Quarters > 0 > ratios > PB
0.008858945586003282
Quarters > 0 > ratios > ROE
2.682777551096109
Quarters > 0 > ratios > ROA
2.1629724609793
Quarters > 0 > ratios > FCF
1218000000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.009560139399076953
Quarters > 0 > health Score
46
Quarters > 1 > quarter
2024-03-31
Quarters > 1 > income Statement > revenue
105569000000
Quarters > 1 > income Statement > cost Of Revenue
25585000000
Quarters > 1 > income Statement > gross Profit
79984000000
Quarters > 1 > income Statement > operating Expenses
89075000000
Quarters > 1 > income Statement > operating Income
16494000000
Quarters > 1 > income Statement > interest Expense
188000000
Quarters > 1 > income Statement > pretax Income
18101000000
Quarters > 1 > income Statement > net Income
14632000000
Quarters > 1 > income Statement > eps
27.34726385859135
Quarters > 1 > income Statement > dividends Per Share
15591000000
Quarters > 1 > income Statement > shares Outstanding
535044386
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
15.623904744764088
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
JPY
Quarters > 1 > balance Sheet > cash
333120000000
Quarters > 1 > balance Sheet > short Term Investments
1658000000
Quarters > 1 > balance Sheet > receivables
116125000000
Quarters > 1 > balance Sheet > inventories
74763000000
Quarters > 1 > balance Sheet > total Current Assets
553644000000
Quarters > 1 > balance Sheet > property Plant Equipment
98755000000
Quarters > 1 > balance Sheet > total Assets
1065883000000
Quarters > 1 > balance Sheet > payables
118063000000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
221914000000
Quarters > 1 > balance Sheet > equity
843969000000
Quarters > 1 > balance Sheet > currency_symbol
JPY
Quarters > 1 > cash Flow > net Income
14632000000
Quarters > 1 > cash Flow > depreciation
5606000000
Quarters > 1 > cash Flow > change In Working Capital
2668000000
Quarters > 1 > cash Flow > cash From Operations
19206000000
Quarters > 1 > cash Flow > capital Expenditures
8554000000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-69963000000
Quarters > 1 > cash Flow > currency_symbol
JPY
Quarters > 1 > ratios > PE
27.34726385859135
Quarters > 1 > ratios > PB
0.009181039585638808
Quarters > 1 > ratios > ROE
1.733712968130346
Quarters > 1 > ratios > ROA
1.372758548546135
Quarters > 1 > ratios > FCF
10652000000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.10090083263079123
Quarters > 1 > health Score
54
Quarters > 2 > quarter
2023-12-31
Quarters > 2 > income Statement > revenue
136180000000
Quarters > 2 > income Statement > cost Of Revenue
34233000000
Quarters > 2 > income Statement > gross Profit
101947000000
Quarters > 2 > income Statement > operating Expenses
98926000000
Quarters > 2 > income Statement > operating Income
37254000000
Quarters > 2 > income Statement > interest Expense
52000000
Quarters > 2 > income Statement > pretax Income
32907000000
Quarters > 2 > income Statement > net Income
27634000000
Quarters > 2 > income Statement > eps
51.40164170675563
Quarters > 2 > income Statement > dividends Per Share
0
Quarters > 2 > income Statement > shares Outstanding
537609288
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
27.35644000587458
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
JPY
Quarters > 2 > balance Sheet > cash
403083000000
Quarters > 2 > balance Sheet > short Term Investments
1923000000
Quarters > 2 > balance Sheet > receivables
119082000000
Quarters > 2 > balance Sheet > inventories
71363000000
Quarters > 2 > balance Sheet > total Current Assets
611124000000
Quarters > 2 > balance Sheet > property Plant Equipment
94508000000
Quarters > 2 > balance Sheet > total Assets
1025942000000
Quarters > 2 > balance Sheet > payables
92983000000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
189524000000
Quarters > 2 > balance Sheet > equity
836418000000
Quarters > 2 > balance Sheet > currency_symbol
JPY
Quarters > 2 > cash Flow > net Income
27634000000
Quarters > 2 > cash Flow > depreciation
5645000000
Quarters > 2 > cash Flow > change In Working Capital
-7488000000
Quarters > 2 > cash Flow > cash From Operations
31266000000
Quarters > 2 > cash Flow > capital Expenditures
10491000000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
20817000000
Quarters > 2 > cash Flow > currency_symbol
JPY
Quarters > 2 > ratios > PE
51.40164170675563
Quarters > 2 > ratios > PB
0.009308333523209688
Quarters > 2 > ratios > ROE
3.303850467110942
Quarters > 2 > ratios > ROA
2.69352458521047
Quarters > 2 > ratios > FCF
20775000000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.15255544132765458
Quarters > 2 > health Score
58
Quarters > 3 > quarter
2023-09-30
Quarters > 3 > income Statement > revenue
106844000000
Quarters > 3 > income Statement > cost Of Revenue
29928000000
Quarters > 3 > income Statement > gross Profit
76915000000
Quarters > 3 > income Statement > operating Expenses
84332000000
Quarters > 3 > income Statement > operating Income
22511000000
Quarters > 3 > income Statement > interest Expense
90000000
Quarters > 3 > income Statement > pretax Income
38292000000
Quarters > 3 > income Statement > net Income
31908000000
Quarters > 3 > income Statement > eps
59.351585601381224
Quarters > 3 > income Statement > dividends Per Share
14515000000
Quarters > 3 > income Statement > shares Outstanding
537609900
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
21.069035228931902
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
JPY
Quarters > 3 > balance Sheet > cash
382266000000
Quarters > 3 > balance Sheet > short Term Investments
847000000
Quarters > 3 > balance Sheet > receivables
113621000000
Quarters > 3 > balance Sheet > inventories
71338000000
Quarters > 3 > balance Sheet > total Current Assets
581362000000
Quarters > 3 > balance Sheet > property Plant Equipment
92877000000
Quarters > 3 > balance Sheet > total Assets
1004051000000
Quarters > 3 > balance Sheet > payables
89426000000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
191908000000
Quarters > 3 > balance Sheet > equity
812143000000
Quarters > 3 > balance Sheet > currency_symbol
JPY
Quarters > 3 > cash Flow > net Income
31908000000
Quarters > 3 > cash Flow > depreciation
5595000000
Quarters > 3 > cash Flow > change In Working Capital
-1139000000
Quarters > 3 > cash Flow > cash From Operations
23944000000
Quarters > 3 > cash Flow > capital Expenditures
6625000000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-
Quarters > 3 > cash Flow > net Change In Cash
10136000000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
59.351585601381224
Quarters > 3 > ratios > PB
0.00958657104943341
Quarters > 3 > ratios > ROE
3.928864744263018
Quarters > 3 > ratios > ROA
3.1779262208792183
Quarters > 3 > ratios > FCF
17319000000
Quarters > 3 > ratios > Piotroski FScore
3
Quarters > 3 > ratios > fcf Percent
0.1620961401669724
Quarters > 3 > health Score
59
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
495558000000
Annuals > 0 > income Statement > cost Of Revenue
132611000000
Annuals > 0 > income Statement > gross Profit
362947000000
Annuals > 0 > income Statement > operating Expenses
403692000000
Annuals > 0 > income Statement > operating Income
91866000000
Annuals > 0 > income Statement > interest Expense
7538000000
Annuals > 0 > income Statement > pretax Income
83453000000
Annuals > 0 > income Statement > net Income
59870000000
Annuals > 0 > income Statement > eps
114.3959309396026
Annuals > 0 > income Statement > dividends Per Share
30895000000
Annuals > 0 > income Statement > shares Outstanding
523357776
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
18.537890620270485
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
JPY
Annuals > 0 > balance Sheet > cash
244681000000
Annuals > 0 > balance Sheet > short Term Investments
1705000000
Annuals > 0 > balance Sheet > receivables
157015000000
Annuals > 0 > balance Sheet > inventories
72933000000
Annuals > 0 > balance Sheet > total Current Assets
504026000000
Annuals > 0 > balance Sheet > property Plant Equipment
111477000000
Annuals > 0 > balance Sheet > total Assets
1067363000000
Annuals > 0 > balance Sheet > payables
121063000000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
216552000000
Annuals > 0 > balance Sheet > equity
850811000000
Annuals > 0 > balance Sheet > currency_symbol
JPY
Annuals > 0 > cash Flow > net Income
59870000000
Annuals > 0 > cash Flow > depreciation
24780000000
Annuals > 0 > cash Flow > change In Working Capital
-43984000000
Annuals > 0 > cash Flow > cash From Operations
67884000000
Annuals > 0 > cash Flow > capital Expenditures
105268000000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
-158402000000
Annuals > 0 > cash Flow > currency_symbol
JPY
Annuals > 0 > ratios > PE
114.3959309396026
Annuals > 0 > ratios > PB
0.008908285520558619
Annuals > 0 > ratios > ROE
7.036815461953359
Annuals > 0 > ratios > ROA
5.609150776258874
Annuals > 0 > ratios > FCF
-37384000000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
-0.0754381929057749
Annuals > 0 > health Score
48
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
442233000000
Annuals > 1 > income Statement > cost Of Revenue
111207000000
Annuals > 1 > income Statement > gross Profit
331026000000
Annuals > 1 > income Statement > operating Expenses
346391000000
Annuals > 1 > income Statement > operating Income
95842000000
Annuals > 1 > income Statement > interest Expense
190000000
Annuals > 1 > income Statement > pretax Income
97246000000
Annuals > 1 > income Statement > net Income
81188000000
Annuals > 1 > income Statement > eps
151.01673615430542
Annuals > 1 > income Statement > dividends Per Share
29027000000
Annuals > 1 > income Statement > shares Outstanding
537609288
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
21.672285876449745
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
JPY
Annuals > 1 > balance Sheet > cash
403083000000
Annuals > 1 > balance Sheet > short Term Investments
1923000000
Annuals > 1 > balance Sheet > receivables
119082000000
Annuals > 1 > balance Sheet > inventories
71363000000
Annuals > 1 > balance Sheet > total Current Assets
611124000000
Annuals > 1 > balance Sheet > property Plant Equipment
94508000000
Annuals > 1 > balance Sheet > total Assets
1025942000000
Annuals > 1 > balance Sheet > payables
92983000000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
189524000000
Annuals > 1 > balance Sheet > equity
836418000000
Annuals > 1 > balance Sheet > currency_symbol
JPY
Annuals > 1 > cash Flow > net Income
50370000000
Annuals > 1 > cash Flow > depreciation
21096000000
Annuals > 1 > cash Flow > change In Working Capital
-9051000000
Annuals > 1 > cash Flow > cash From Operations
115552000000
Annuals > 1 > cash Flow > capital Expenditures
32852000000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
-
Annuals > 1 > cash Flow > net Change In Cash
63889000000
Annuals > 1 > cash Flow > currency_symbol
JPY
Annuals > 1 > ratios > PE
151.01673615430542
Annuals > 1 > ratios > PB
0.009308333523209688
Annuals > 1 > ratios > ROE
9.706629938619207
Annuals > 1 > ratios > ROA
7.9135077811416235
Annuals > 1 > ratios > FCF
82700000000
Annuals > 1 > ratios > Piotroski FScore
3
Annuals > 1 > ratios > fcf Percent
0.18700549257970345
Annuals > 1 > health Score
68
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
398371000000
Annuals > 2 > income Statement > cost Of Revenue
86915000000
Annuals > 2 > income Statement > gross Profit
311455000000
Annuals > 2 > income Statement > operating Expenses
315996000000
Annuals > 2 > income Statement > operating Income
82374000000
Annuals > 2 > income Statement > interest Expense
1088000000
Annuals > 2 > income Statement > pretax Income
67572000000
Annuals > 2 > income Statement > net Income
53573000000
Annuals > 2 > income Statement > eps
99.67592718352851
Annuals > 2 > income Statement > dividends Per Share
25258000000
Annuals > 2 > income Statement > shares Outstanding
537471800
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
20.67770997386858
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
JPY
Annuals > 2 > balance Sheet > cash
339194000000
Annuals > 2 > balance Sheet > short Term Investments
526000000
Annuals > 2 > balance Sheet > receivables
111746000000
Annuals > 2 > balance Sheet > inventories
70675000000
Annuals > 2 > balance Sheet > total Current Assets
542189000000
Annuals > 2 > balance Sheet > property Plant Equipment
89099000000
Annuals > 2 > balance Sheet > total Assets
939881000000
Annuals > 2 > balance Sheet > payables
70922000000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
177055000000
Annuals > 2 > balance Sheet > equity
762826000000
Annuals > 2 > balance Sheet > currency_symbol
JPY
Annuals > 2 > cash Flow > net Income
53573000000
Annuals > 2 > cash Flow > depreciation
18476000000
Annuals > 2 > cash Flow > change In Working Capital
-23218000000
Annuals > 2 > cash Flow > cash From Operations
48672000000
Annuals > 2 > cash Flow > capital Expenditures
28666000000
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
-
Annuals > 2 > cash Flow > net Change In Cash
4111000000
Annuals > 2 > cash Flow > currency_symbol
JPY
Annuals > 2 > ratios > PE
99.67592718352851
Annuals > 2 > ratios > PB
0.010203724843673392
Annuals > 2 > ratios > ROE
7.022964607918452
Annuals > 2 > ratios > ROA
5.69997691197077
Annuals > 2 > ratios > FCF
20006000000
Annuals > 2 > ratios > Piotroski FScore
3
Annuals > 2 > ratios > fcf Percent
0.05021951899109122
Annuals > 2 > health Score
53
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
352246000000
Annuals > 3 > income Statement > cost Of Revenue
87849000000
Annuals > 3 > income Statement > gross Profit
264398000000
Annuals > 3 > income Statement > operating Expenses
291136000000
Annuals > 3 > income Statement > operating Income
61111000000
Annuals > 3 > income Statement > interest Expense
1117000000
Annuals > 3 > income Statement > pretax Income
60050000000
Annuals > 3 > income Statement > net Income
52347000000
Annuals > 3 > income Statement > eps
97.42090896430794
Annuals > 3 > income Statement > dividends Per Share
24176000000
Annuals > 3 > income Statement > shares Outstanding
537328183
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
17.34895499168195
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
JPY
Annuals > 3 > balance Sheet > cash
335084000000
Annuals > 3 > balance Sheet > short Term Investments
1434000000
Annuals > 3 > balance Sheet > receivables
104275000000
Annuals > 3 > balance Sheet > inventories
64089000000
Annuals > 3 > balance Sheet > total Current Assets
518231000000
Annuals > 3 > balance Sheet > property Plant Equipment
78652000000
Annuals > 3 > balance Sheet > total Assets
921872000000
Annuals > 3 > balance Sheet > payables
64652000000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
184710000000
Annuals > 3 > balance Sheet > equity
737162000000
Annuals > 3 > balance Sheet > currency_symbol
JPY
Annuals > 3 > cash Flow > net Income
52347000000
Annuals > 3 > cash Flow > depreciation
19498000000
Annuals > 3 > cash Flow > change In Working Capital
23852000000
Annuals > 3 > cash Flow > cash From Operations
86546000000
Annuals > 3 > cash Flow > capital Expenditures
19766000000
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-
Annuals > 3 > cash Flow > net Change In Cash
48065000000
Annuals > 3 > cash Flow > currency_symbol
JPY
Annuals > 3 > ratios > PE
97.42090896430794
Annuals > 3 > ratios > PB
0.010556141996204362
Annuals > 3 > ratios > ROE
7.101152799520323
Annuals > 3 > ratios > ROA
5.678337122724196
Annuals > 3 > ratios > FCF
66780000000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.18958341613531451
Annuals > 3 > health Score
68
Valuation > metrics > PE
30.8128
Valuation > metrics > PB
0.008858945586003282
Valuation > final Score
63.02464
Valuation > verdict
37.9% Undervalued
Profitability > metrics > ROE
2.682777551096109
Profitability > metrics > ROA
4.258952559714401
Profitability > metrics > Net Margin
0.18165834667671343
Profitability > final Score
45
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.2403197911643607
Risk > metrics > Interest Coverage
33.65294924554184
Risk > final Score
100
Risk > verdict
Low
Liquidity > metrics > Current Ratio
4.735892631487211
Liquidity > metrics > Quick Ratio
4.061614885180182
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
67.18328336969037
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
32
Prev Profitabilities > 1
50
Prev Profitabilities > 2
54
Prev Risks > 0
100
Prev Risks > 1
100
Prev Risks > 2
100
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:07:10.108Z
Earnings History > 0 > period
2026-03-31
Earnings History > 0 > report Date
2026-04-29
Earnings History > 0 > date
2026-03-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-12-31
Earnings History > 1 > report Date
2026-02-04
Earnings History > 1 > date
2025-12-31
Earnings History > 1 > before After Market
BeforeMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachromatic leukodystrophy; Orkedia for treatment of secondary hyperparathyroidism; and Romiplate to treat aplastic anemia. It also develops OTL-203 for the treatment of mucopolysaccharidosis type IH (hurler syndrome); KHK4083/AMG 451 to treat atopic dermatitis, prurigo nodularis, and asthma; OTL-201 for the treatment of mucopolysaccharidosis type IIIA (sanfilippo syndrome type A); ziftomenib for treating R/R acute myeloid Leukemia and acute lymphoblastic leukemia; KHK4951 for the treatment of diabetic macular edema and neovascular age-related macular degeneration; KK8123 to treat x-linked hypophosphatemia; KK2845 for the treatment of acute myeloid leukemia; KK4277 for treating systemic and cutaneous lupus erythematosus; Lumicef to treat palmoplantar pustulosis; KK2260 and KK2269 for the treatment of solid tumors; and KK8398 for the treatment of achondroplasia. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ABridgeBio Stock: Next Chapter Begins After Attruby Approval (NASDAQ:BBIO) Seeking Alpha
Read more →Why The Small Orchard Therapeutics Buyout Is Worth A Look (NASDAQ:ORTX) Seeking Alpha
Read more →(Last Updated 2024-06-30)
Health Score
Price to Earnings Ratio (P/E)
-
Medium
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Kyowa Kirin Co., Ltd.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2024-06-30)
(Last Updated 2024-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2024-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2024-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.